Saskatchewan residents with ALS may benefit from adding two new medications to the Saskatchewan Drug Plan Formulary.
The Government of Saskatchewan announced that it is expanding treatment options for those living with ALS by listing Albrioza (sodium phenylbutyrate and ursodoxicoltaurine) and the oral suspension of Radicava (edaravone) on the Saskatchewan Drug Plan Formulary.
Effective September 1, eligible ALS patients who meet specific medical criteria may be considered for coverage of these medications under the Saskatchewan Drug Plan.
Minister of Health Everett Hindley said providing patients living with ALS additional treatment options is crucial.
“Saskatchewan residents living with ALS know how debilitating this disease can be. Including these medications on the Saskatchewan Formulary gives patients access to potentially life-changing treatments.”
The Government notes that while there is no cure for ALS, medications such as Albrioza and Radicava may help slow the rate of disease progression.
Patients and families who think they or their family members may benefit from therapy with these medications are encouraged to speak with their physician.
